NSE · AKUMS
Akums Drugs & Pharmaceuticals Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹338 Cr with net profit ₹15 Cr — a 4.49% net margin, versus 5.69% the period before.
Shareholding
As of 2026-06-30
- Promoter75.26%
- Public9.39%
- FII1.91%
- DII13.44%
70,289 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.75× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Drug Manufacturers - Specialty & Generic · ranked #1 of 15 by market cap
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Akums Drugs & Pharmaceuticals Ltd.(this company) | — | 120.17 | 3.07 | — | — |
AI analysis
AI-generated · google/gemini-2.5-flashAkums Drugs & Pharmaceuticals Ltd. (symbol: 544222) operates in the Healthcare sector, manufacturing and selling pharmaceutical products and active pharmaceutical ingredients in India and internationally. The company provides a range of products including drugs, ayurvedic, nutraceuticals, food and dietary supplements, and also operates as a pharmaceutical contract development and manufacturing company. The company has a market capitalization of Rs 10960 Cr.
Positives
- +The company's debt-to-equity ratio of 0.04 indicates a low level of financial leverage.
- +Promoter holding is high at 75.26% as of June 30, 2026, which can indicate confidence from the promoters.
- +The dividend yield is 42%, which is a high payout to shareholders.
Negatives
- −Promoter holding decreased from 84.91% in February 2024 to 75.26% in June 2026.
- −Profit margin is relatively low at 5.85%.
- −Return on Equity (ROE) is 7.7%, which may be considered modest.
- −Return on Capital Employed (ROCE) is 10.95%, which may be considered moderate.
Business
Akums Drugs & Pharmaceuticals Ltd. is engaged in the manufacturing and sale of pharmaceutical products and active pharmaceutical ingredients. Its offerings span various categories such as drugs, ayurvedic products, nutraceuticals, food and dietary supplements, and derma and cosmetics. The company also provides branded formulations in multiple dosage forms and therapeutic areas, and offers contract development and manufacturing services. Akums was incorporated in 2004 and is headquartered in Delhi, India.
Financial Performance
The company reported an annual revenue of Rs 4361.41 Cr, with a net profit of Rs 255.19 Cr for the period ending March 2026. Quarterly revenue stood at Rs 1157.87 Cr and net profit at Rs 84.61 Cr for March 2026. For December 2025, quarterly revenue was Rs 1159.59 Cr and net profit Rs 66.32 Cr.
Profitability & Returns
Akums Drugs & Pharmaceuticals Ltd. achieved a profit margin of 5.85%. The company's Return on Equity (ROE) was 7.7% and Return on Capital Employed (ROCE) was 10.95%. Earnings per share (EPS) for the period ending March 2026 was Rs 16.67.
Balance Sheet
The company maintains a low debt-to-equity ratio of 0.04, indicating minimal reliance on debt financing. The book value per share is reported at Rs 210.57.
Ownership & Pledges
As of June 30, 2026, promoter holding in Akums Drugs & Pharmaceuticals Ltd. was 75.26%. Foreign Institutional Investor (FII) holding was 1.91%, while Domestic Institutional Investor (DII) holding was 13.44%. Public shareholding stood at 9.39%. There are no reported promoter share pledges.
Data as of — price: 2026-07-29 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Akums Drugs & Pharmaceuticals Ltd.share price & fundamentals